Global Microbiome Therapeutic and Diagnostic Market Worth to $2.7 billion in 2023

Mar 8, 2019

Global Microbiome Therapeutics & Diagnostics Market presents Financial market forecast through 2023 with CAGR values of all market segments outlined in the objective, SWOT analysis of the global market and Geographical analysis and challenges within key topographies.

Pune, India - March 8, 2019 /MarketersMedia/ —

This report provides a comprehensive overview of the size of the microbiome therapeutic and diagnostic market, segmentation of the market (Gastrointestinal, Metabolic, Cancer, Neurological, Autoimmune, Skin), key players and the potential of therapies that are in clinical trials. Kelly Scientific analysis indicates that the global Microbiome Therapeutic and Diagnostic Market is worth $1.13 billion in 2018 and will grow at a CAGR of 19.03% over five years to $2.7 billion in 2023. The majority of the market will be dominated by microbiome based therapeutics, with an estimate of x%, compared to x% in microbiome diagnostics. This report describes the evolution of such a prospective market in eight chapters supported by over 82 tables and figures in 165 pages.

An overview of the human microbiome space that includes how the market is sub-divided into therapeutics (prebiotics, probiotics, fecal microbiota transplantation, small molecules) and diagnostics.
Global microbiome market, global breakdown, application breakdown and leading market players
Detailed account of the microbiome industry market by geography, indication and company profiles
Profiles, pipeline products, financial analysis and business strategy of the major companies in this space
Focus on current trends, business environment, pipeline products, clinical trials, and future market forecast for microbiome therapeutics and diagnostics
Insight into the challenges faced by stakeholders
Insight into the biobanking industry globally and its impact on the overall market
Description and data for the prevalence of disease types that are addressed by harnessing the human microbiota

Get Free Sample Copy of Global Microbiome Therapeutic and Diagnostic Market Research Report at https://www.reportsnreports.com/contacts/requestsample.aspx?name=1653034

The global microbiome therapeutic and diagnostic market is worth $1.13 billion in 2018 and will grow at a CAGR of 19.03% over five years to $2.7 billion in 2023. The majority of the market will be dominated by microbiome based therapeutics, with an estimate of x%, compared to x% in microbiome diagnostics. Therefore, the global microbiome therapeutics market is worth $x billion in 2018, compared to $x billion in the diagnostic space. By 2023, therapeutics will grow to $x billion, and diagnostics will grow to $x billion globally. Growth will certainly depend on a number of factors including positive results from clinical trials, continued investment and regulatory strategies.

Our analysis indicates that North America holds the lions share of the microbiome therapeutic and diagnostic market in 2018 at $x million. This compares to $x million in Europe, $x million in Asia Pacific, and $x million in the Middle East. By 2023, North America will continue to dominate the market, with a revenue of $x billion, compared to $x million in Europe, $x million in Asia Pacific, and $x million in the Middle East.

Market Applications & Therapeutic Areas
Our Analysis has identified six key therapeutic areas that the microbiome therapeutic and diagnostic market is sub-divided into, namely:
Gastrointestinal
Metabolic
Cancer
Neurological
Autoimmune
Skin Disorders

The gastrointestinal therapeutic market is the most dominant, demanding $x million in revenue in 2018, which will rise to $x million by 2023. This is mainly due to disease states such as Clostridium difficile infection, Crohn s disease, ulcerative colitis and gastroenteritis. As mentioned throughout our report, this is the key area for active clinical trials and impending drug launches. This area currently demands x% of the overall market and will tend to dominate this space for the foreseeable future. The gastrointestinal diagnostic market is currently worth $x million and is set to reach $x million by 2023.

Get Discount on this Research Report at https://www.reportsnreports.com/contacts/discount.aspx?name=1653034

Competitive Landscape
The microbiome field is highly competitive, especially within the inflammatory bowel disease and Clostridium difficile infection therapeutic markets. A wide range of big pharma, biotech, early-stage companies, academic institutions, government agencies and other public and private research organizations are involved in this space. The main therapeutic competitors within the microbiome industry are as follows:
Johnson & Johnson
Novartis International
Abbvie
Takeda
Merck & Co.,
Bristol Myers Squibb
Pfizer
Seres Therapeutics
Vedanta Biosciences
Finch Therapeutics
Enterome Bioscience
Second Genome

More specifically, companies involved in C. difficile infection include Actelion Pharmaceutical, Assembly Biosciences, AzurRx, Da Volterra, Pfizer, Merck, Merus, Rebiotix, Sanofi, Seres Therapeutics, Synthetic Biologics and Summit Therapeutics. Companies within the IBS-Constipation market include Ardelyx, Allergan, Ironwood Pharmaceuticals, Synergy Pharmaceuticals, Synthetic Biologics and Takeda. Within the pertussis market GlaxoSmithKline, Mitsubishi Tanabe Pharma Corporation and Sanofi are major players. BioMarin Pharmaceutical, Synthetic Biologics, Codexis and Synlogic are involved in the PKU market. Within the diagnostic sub-market, the following are the main players:
Metabiomics - Colon Polyp and Colon Cancer Test
Origin Sciences - Colorectal Cancer (CRC) Test
Enterome/AbbVie - IBD110

Direct Purchase of this Research Report at https://www.reportsnreports.com/purchase.aspx?name=1653034

Key Questions Answered
What are the Main Microbiome Therapeutics in the Pipeline?
What are the Main Microbiome Diagnostics in the Pipeline?
What Key Biologics are in the Pipeline?
How Many Human Therapeutic and Diagnostic Microbiome Products are in the Pipeline?
What is the Human Therapeutic Pipeline like by Drug, Company and Stage of Development?
What Microbiome Therapeutics are in the Clostridium Difficile Infection Pipeline?
Who are the Major Players in the Therapeutic and Diagnostic Spaces?
What will the Microbiome Therapeutic Market be Worth in 2023?
What will the Microbiome Therapeutic Sub-Markets (Gastrointestinal, Metabolic, Cancer, Neurological, Autoimmune, Skin) be Worth in 2023?
What will the Microbiome Diagnostic Market be Worth in 2023?
What will the Microbiome Diagnostic Sub-Markets (Gastrointestinal, Metabolic, Cancer, Neurological, Autoimmune, Skin) be Worth in 2023?
What are the Main Drivers, Threats and Opportunities of these Markets?
What were the Most Influential Market Deals to Date?
How Much Venture Capital has Been Invested in the Microbiome Industry?
What Major Microbiome Companies have Received Investment?
What Microbiota are Associated with Cancer Development?
How does Gut Dysbiosis influence the Host Inflammatory Response?
Is there an Association Between the Development of Diabetes and Our Microbiota?
How does Clostridium difficile Infection Impact the Microbiome?
What Host-Microbe Interactions Occur During the Pathogenesis of Dental Caries?
During Cirrhosis of the Liver, What Brain Dysfunction Occurs Due to Gut Dysbiosis?
What are the Main Therapeutic Intervention Strategies for Microbiome Dysbiosis
What Safety Requirements are Needed for Microbiome Therapeutics?
What Clinical Trials are Investigating Probiotics and Obesity?
What Clinical Trials are Investigating Probiotics and Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease?
What Clinical Trials are Investigating Probiotics and Irritable Bowel Syndrome?
What Clinical Trials are Investigating Probiotics and Obesity?
How Has the Human Microbiome Project Investigated IBD, Prediabetes and Pregnancy?
How does the Human Microbiome Differ Between Geographical Areas and Bodily Locations?

Countries Covered
Global,North America, Europe, Asia/Pacific, Middle East/Africa, ROC

Contact Info:
Name: Vishal Kalra
Email: Send Email
Organization: ReportsnReports
Website: https://www.reportsnreports.com/reports/1653034-global-microbiome-therapeutics-diagnostics-market-analysis-forecast-to-2023.html

Source URL: https://marketersmedia.com/global-microbiome-therapeutic-and-diagnostic-market-worth-to-27-billion-in-2023/490116

Source: MarketersMedia

Release ID: 490116

More News

4 bird species newly recorded in protected landscape in Rizal
Oct 19, 2026
4 bird species newly recorded in protected landscape in Rizal

LUCENA CITY — The Department of Environment and Natural Resources (DENR) identified four additional bird species in the Pamitinan Protected Landscape (PPL), enriching the area’s biodiversity profile. In a report on Sunday, the DENR office in the Calabarzon region identified the newly recorded species as the Philippine Dwarf Kingfisher (Ceyx melanurus), Philippine Frogmouth (Batrachostomus septimus),

Glaiza De Castro gets surprise baby shower from her showbiz friends
Oct 19, 2026
Glaiza De Castro gets surprise baby shower from her showbiz friends

Glaiza De Castro's showbiz friends organized a surprise baby shower for the mom-to-be!

INQToday: Raffy Tulfo overtakes Padilla in Octa’s 2028 Senate survey
Oct 19, 2026
INQToday: Raffy Tulfo overtakes Padilla in Octa’s 2028 Senate survey

MANILA, Philippines — Here are INQToday’s top stories this afternoon: Gasoline prices are set to drop by P4.30 per liter on Tuesday, while diesel prices will increase by P2.60 per liter; the Department of Foreign Affairs says no Filipinos have been reported harmed in protests in France and Italy; and Sen. Raffy Tulfo has overtaken

Gawilan bags Philippines’ first gold at 2026 Asian Para Games
Oct 19, 2026
Gawilan bags Philippines’ first gold at 2026 Asian Para Games

Veteran para swimmer Ernie Gawilan delivers for the Philippines anew, winning the country’s first gold at the 2026 Asian Para Games in Japan

House upped budget for multi-purpose buildings, local roads by P170 billion --watchdog
Oct 19, 2026
House upped budget for multi-purpose buildings, local roads by P170 billion --watchdog

The House of Representatives increased, by P170 billion, the budget for multi-purpose buildings and local access roads in the proposed 2027 national budget, a watchdog group said Monday

Witness admits seeing up to 60 ‘maleta’ at Zaldy Co’s condo
Oct 19, 2026
Witness admits seeing up to 60 ‘maleta’ at Zaldy Co’s condo

MANILA, Philippines — A prosecution witness told the Sandiganbayan Third Division on Monday that he saw up to 60 “maleta” moved in and out of the luxury condominium of  former Ako Bicol Rep. Zaldy Co, and was told by colleagues that it contained cash. Maj. Alvin Nuguid, who served as close-in security of Co, made

Elderly woman arrested in Quezon drug bust; P191,000 shabu seized
Oct 19, 2026
Elderly woman arrested in Quezon drug bust; P191,000 shabu seized

LUCENA CITY — A 61-year-old woman was arrested on Sunday in a drug bust in Unisan, Quezon, for allegedly selling shabu (crystal meth) to an undercover operative. In a report on Monday, the Quezon Police Provincial Office said members of the local police drug enforcement unit arrested the woman at 12:54 p.m. in Barangay F.

Urdaneta gets new leaders after dismissal of mayor, vice mayor
Oct 19, 2026
Urdaneta gets new leaders after dismissal of mayor, vice mayor

CALASIAO, Pangasinan – Councilor Blesildo Sumera assumed the mayoralty seat of Urdaneta City on Monday after taking his oath of office on Friday. Sumera’s ascension to mayor followed the Office of the Ombudsman’s dismissal of Mayor Julius “Rammy” Parayno and Vice Mayor Jimmy Parayno for “grave misconduct.” They defied a 2025 Palace suspension order that

Akmal won't back down from those in power, wishes 'happy campaigning'
Oct 19, 2026
Akmal won't back down from those in power, wishes 'happy campaigning'

Malacca exco also says he won't step down.

53 groups to join Belenismo 2026; Hall of Famers to offer bigger attractions
Oct 19, 2026
53 groups to join Belenismo 2026; Hall of Famers to offer bigger attractions

Giant and grand Belen displays are now under construction in Tarlac for the annual Belenismo in the province.

Shaping the future of Filipino dining
Oct 19, 2026
Shaping the future of Filipino dining

The Unilever Food Solutions Culinary Team explores how today’s chef balances tradition with innovation

1PWD party-list: ADHD diagnosis not an excuse to mock PWDs
Oct 19, 2026
1PWD party-list: ADHD diagnosis not an excuse to mock PWDs

MANILA, Philippines — An Attention-Deficit/Hyperactivity Disorder (ADHD) diagnosis should not excuse a person from making insensitive remarks about persons with disabilities (PWDs), 1PWD Party-list Rep. JD Castro said Monday. This came after Machong Chismisan podcast host Tito P said he has ADHD, which can affect impulse control and filtering thoughts, following his “walang kuwenta (useless)”

YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.

Voice of KL

We may be unheard, but things are different now. Voice of KL represents the voice of Malaysians who want you to discover the beautiful and developed city of Malaysia.